MAULANA AZAD MEDICAL COLLEGE

Aethlon Medical Advances Hemopurifier Trial for Solid Tumors Resistant to Anti-PD-1 Therapy

6 months ago

• Aethlon Medical has enrolled the first two patients in its Hemopurifier® trial in Australia, targeting solid tumors unresponsive to anti-PD-1 antibodies. • The trial is a safety, feasibility, and dose-finding study, with two Australian sites now actively enrolling patients and an additional site in India approved. • Strategic cost-cutting measures are being implemented to optimize resource allocation, focusing on high-impact areas of the oncology trial. • The Hemopurifier aims to remove extracellular vesicles (EVs) from the bloodstream, potentially improving response rates to anti-PD-1 therapies.